Functional significance of angiotensin receptors in human myocardium. Significant differences between atrial and

C Holubarsch1, S Schmidt-Schweda, A Knorr

  • 1Department of Cardiology and Angiology, University of Freiburg, Germany.

European Heart Journal
|December 1, 1994
PubMed

Insights

Angiotensin (Ang) I and II significantly increased human atrial muscle force, an effect blocked by saralasine. These peptides did not impact ventricular contractility, indicating specific atrial effects mediated by AT1 receptors.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology
  • Human Cardiac Tissue Studies

Background:

  • The renin-angiotensin system plays a crucial role in cardiovascular regulation.
  • Understanding the specific effects of angiotensin peptides on human heart muscle is vital for cardiovascular research.

Purpose of the Study:

  • To investigate the inotropic effects of angiotensin I and II on isolated human cardiac tissues.
  • To determine the receptor subtypes mediating these effects in human atrial tissue.

Main Methods:

  • Isolated human atrial and ventricular muscle preparations were studied under physiological conditions.
  • The effects of angiotensin I and II on developed force were measured.
  • Receptor blockade was employed using saralasine, prazosin, and propranolol to identify mediating pathways.

Main Results:

  • Angiotensin I and II increased peak developed force in human atrial muscles by 30-40%.
  • This positive inotropic effect was abolished by saralasine, indicating angiotensin receptor involvement.
  • No significant inotropic effects of Angiotensin I or II were observed in human ventricular preparations.

Conclusions:

  • Angiotensin I and II exert a positive inotropic effect specifically on human atrial muscle.
  • The observed atrial effects are mediated predominantly by the AT1 receptor subtype.
  • Angiotensin peptides do not significantly influence contractility in human ventricular tissues.

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chambers of the Heart01:16

Chambers of the Heart

The human heart is a complex organ made up of four chambers: the right and left atria and the right and left ventricles. These internal chambers are separated by partitions known as the interatrial and interventricular septa. The exterior of the heart features a groove known as the coronary sulcus that demarcates the atria from the ventricles, while the anterior and posterior interventricular sulci distinguish between the two ventricles.
Deoxygenated blood from the body is received in the right...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...